deaths from compounded semaglutide Troubling Findings in Study of GLP-1 Compounders Novo Nordisk CEO warns of

Impression (whether a consumer has a positive or negative impression of a brand) has also taken hit, falling from 15.6 in 2021 to 12.6 in 2023

Some findings suggested that patients using GLP-1 medications were less likely to progress to advanced or metastatic disease

Murata et al., 2001)

BPC-157 Cytoprotective Peptide TB-500 Actin-Sequestering Peptide Effectiveness Profile At a Glance Verdict BPC-157 wins for fast-acting, localized soft-tissue repair (tendons, ligaments, GI lining), ease of self-administration (can be taken orally or injected), and predictable side-effect profile with virtually no transient reactions at effective doses

One is Virta Health, which advertises its nutrition-focused weight management program as "a proven approach for deprescribing GLP-1s when clinically appropriate." A Virta-funded study assessed 154 people with Type 2 diabetes who stopped using GLP-1 medications but continued following Virta's program, concluding that their weight did not significantly increase after a year